Context.-The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than for adults.
APPROXIMATELY 1 in 200 young persons has obsessive-compulsive disorder (OCD), 1 which many believe to be the paradigmatic neuropsychiatric illness. 2 Individuals with OCD experience obsessions, which are recurrent and persistent thoughts, images, or impulses that are egodystonic, intrusive, and, for the most part, acknowledged as senseless. Common obsessions are generally accompanied by distressing negative affects, such as fear, disgust, doubt, or a feeling of incompleteness, and include contamination fears, scrupulosity, fear of harm to self or others, symmetry urges, or hoarding urges. Not surprisingly, persons with OCD typically attempt to ignore, suppress, or neutralize obsessive thoughts and associated feelings by performing compulsions, which are repetitive, purposeful behaviors that are usually performed according to certain rules or in a stereotyped fashion to temporarily neutralize or alleviate obsessions and their accompanying dysphoric affects. 4 Compulsions can be observable behaviors (eg, hand washing) or covert mental acts (eg, counting). Among children and adolescents with OCD, few receive a correct diagnosis and even fewer receive appropriate treatment. 1 An extensive empirical literature demonstrates that the potent serotonin reuptake inhibitors (SRIs) clomipramine hydrochloride, 5 fluoxetine, 6 fluvoxamine, 7 paroxetine, 8 and sertraline hydrochloride 9 are effective treatments for adults with OCD. Although empirical support is more limited, pharmacotherapy for children and adolescents with OCD also relies on SRIs. 10 The earliest pediatric studies were conducted with the tricyclic compound clomipramine. 5 In the mid 1980s, Flament et al 11 reported that clomipramine was statistically superior to placebo in a placebo-controlled, doubleblind, crossover study. Leonard et al 12 then showed that clomipramine was superior to the predominantly noradrenergic reuptake inhibitor desipramine hydrochloride. Subsequently, an 8-week multicenter, double-blind, parallel comparison of clomipramine vs placebo led to US Food and Drug Administration approval of clomipramine for the treatment of OCD in children and adolescents aged 10 years and older. 13 Unfortunately, clomipramine causes a wide spectrum of anticholinergic, antihistaminergic, and antiadrenergic adverse effects, including excessive sedation, weight gain, adverse cardiovascular effects, and an increased risk for drug-inducedseizures.
14 Thesedifficultiesencouragedthesearchformoreeffectiveandbetter-tolerated treatments for young persons with OCD. 15 One such agent is the selective serotonin reuptake inhibitor (SSRI) sertraline, a naphthylamino compound that specifically blocks neuronal reuptake of serotonin via competitive inhibition at the presynaptic serotonin transporter. 16 Controlled trials of sertraline in adultswithOCDdemonstratethatsertraline is more effective than placebo 17 at doses ranging from 50 to 200 mg 9 and that benefits are maintained with continued drug treatment. 18 Controlled studies of fluoxetine and fluvoxamine 19 in pediatric OCD suggest benefits comparable with those seen with clomipramine. 13 As yet, to our knowledge there have been no published studies regarding the safety and efficacy of sertraline in pediatric OCD. We report the results of a 12-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial of sertraline vs placebo in children and adolescents aged 6 to 17 years with OCD. The primary hypothesis was that sertraline would prove to be a well-tolerated and effective short-term treatment for pediatric OCD.
METHODS

Experimental Design
The trial began with a 1-week singleblind placebo lead-in to eliminate placebo responders even though placebo responses in pediatric OCD appear minimal. 20 Following the placebo lead-in, patients were randomized within site to 12 weeks of double-blind flexibledose treatment using a computer-generated randomization algorithm. To ensure that the age distribution was similar for each treatment condition, patients were stratified into 2 age groups: children (aged 6-12 years) and adolescents (aged 13-17 years). Twelve sites representing all major geographic regions in the United States participated in the study, which passed human subjects review at each of the participating institutions. All investigators obtained assent of the child or adolescentandwritteninformedconsentfrom parents or legal guardians.
Inclusion and Exclusion Criteria
Patients were male and female outpatients aged 6 to 17 years who met full Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R) diagnostic criteria 21 for OCD on clinical interview. At the baseline visit, patients were required to have a score of at least 7 on the National Institute of Mental Health Global Obsessive Compulsive Rating Scale (NIMH GOCS), 22 indicating at least moderate impairment in global functioning from OCD, and a score of 17 or less plus a score of 0 (none) or 1 (minimal) on item 1 (depressed mood) of the 24-item Hamilton Depression Scale, indicating the absence of significant depression. Baseline electrocardiographic and laboratory results were required to be normal or not clinically significant if outside the normal range.
Patients having a primary psychiatric disorder other than OCD on clinical interview were excluded, as were those with medical contraindications to treatment with sertraline or who had participated in aprevioussertralinestudyorbeentreated with sertraline. Treatment with a neuroleptic, anxiolytic, or antidepressant medication within 2 weeks (or fluoxetine within 5 weeks) prior to the initiation of doubleblind treatment or concomitant therapy with any other psychotropic medication was prohibited. Adolescent females of childbearing potential were required to have a negative result for a serum ␤-human chorionic gonadotropin pregnancy test on day 1 of the placebo lead-in phase. Patientswerenotpermittedtoreceivebehavior therapy or any other form of psychotherapy during the course of the study.
Medication Procedures
Sertraline hydrochloride and pill placebo were packaged in identical blister packs of 25-mg sertraline hydrochloride tablets or identical placebo tablets. The starting dosage for both active treatment and placebo was 25 mg/d for children and 50 mg/d for adolescents. To maximize efficacy, although perhaps at the cost of more adverse effects in those treated with sertraline, dosages were titrated upward in a forced titration procedure by 50 mg/ wk to a maximum dosage of 200 mg/d or their maximum tolerated dose during the first 4 weeks of double-blind treatment following a predefined dosing schedule. Further dosage adjustment was permitted only in the event of dose-limiting adverse experiences.
Measures
The primary efficacy measures were the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), the NIMH GOCS, and the NIMH Clinical Global Impression of Severity of Illness (CGI-S) and Improvement (CGI-I) scales. The CY-BOCS is identical in form and scoring to the widely used adult YaleBrown Obsessive Compulsive Scale, 22 but the questions are slightly modified for age appropriateness. 23 The CY-BOCS scale ranges from 0 to 40, with a score of 20 indicating moderate severity of obsessive and compulsive symptoms and a score of 10 or below indicating subclinical OCD. The NIMH GOCS has been extensively used in both adult 22 and pediatric 12 OCD trials. It assesses severity of OCD symptoms in relation to their functional impact. 24 Scores of 1 to 3 indicate minimal impairment, scores of 7 or more indicate clinically meaningful OCD symptoms, and scores of 13 to 15 indicate very severe obsessive and compulsive behaviors. The NIMH CGI scales provided clinicianrated overall summary: the CGI-S scale ranges from 1 (normal, not at all ill) to 7 (extremely ill) and the CGI-I scale ranges from 1 (very much improved judgments) to 7 (very much worse judgments). 25 Efficacy measures were obtained on day 1 of the placebo lead-in phase, 1 week later at the end of the placebo lead-in phase (baseline), and at the end of weeks 1, 2, 4, 6, 8, 10, and 12 of double-blind treatment (or at the time of early termination). Vital signs (eg, blood pressure, pulse) and body weight were recorded at every study visit as were all adverse experiences volunteered by the patient or observed by the investigator. Blood samples for routine hematology and serum chemistry studies and urine samples for routine urinalysis were obtained on day 1 of the placebo lead-in phase and at the end of weeks 1, 2, 4, 6, 8, 10, and 12 of doubleblind treatment. A 12-lead electrocardiogram was obtained on day 1 of the placebo lead-in phase and at the end of weeks 1, 4, and 12 of double-blind treatment.
Statistical Analyses
For the efficacy parameters, analysis of covariance models were used, including baseline and any additional postbaseline efficacy data. Except for the CGI-I score, the baseline value was added to the model as a covariate so that the full statistical model included terms for treatment, site, treatment-by-site interaction, age group (6-12 years and 13-17 years), sex, and the interactions of age group and treatment, sex and age group, sex and treatment, and sex, age group, and treatment. Age, weight, Hamilton Depression Scale score, and duration of illness were compared at baseline between the treatment groups using analyses of variance with terms for site and treatment group. Sex, race, and socioeconomic status were compared us-ing 2 tests.Changesfrombaselineinlaboratory and vital sign parameters between treatment groups were compared using analysis of variance. The incidence of adverse events was compared between treatment groups using the Fisher exact test. Mean change from baseline to end point in body weight was compared between treatment groups using the Wilcoxon rank sum test. All statistical tests were 2-sided at the .05 ␣ level of significance; assumptions underlying the chosen statistical models were examined prior to conducting the analyses. Figure 1 shows patient flow through all phasesofthestudy.Twopatientsrandomized to receive sertraline were excluded from the data analyses reported herein. One received active medication and another withdrew consent during the placebo lead-in phase. Full intent-to-treat efficacy analyses including these 2 patients did not appreciably change the results on the main dependent measures. There were no placebo lead-in responders.
RESULTS
Sample Characteristics
One hundred eighty-seven patients entered the double-blind phase of the study and all received at least 1 dose of study medication. Ninety-two patients (53 children and 39 adolescents) were randomized to receive sertraline and 95 (54 children and 41 adolescents) were randomized to receive placebo. The pooled mean age for sertraline and placebo treatment groups was 12.6 years (10.4 years in children and 15.5 years in adolescents). Among the children, the average duration of OCD was 3.4 years and 4.2 years for the sertraline and placebo groups, respectively. Among the adolescents, the average duration of OCD was 6.1 years and 5.5 years for the sertraline and placebo groups, respectively. Mean baseline scores by treatment group for each of the efficacy measures reveal a patient sample with moderate to severe OCD. The mean CYBOCS score at baseline was 23.4 for patients randomized to sertraline and 22.2 for patients randomized to placebo. The mean NIMH-GOCS score at baseline was 9.2 for patients randomized to sertraline and 9.1 for patients randomized to placebo. The mean CGI-S score was 4.7 for patients randomized to sertraline and 4.6 for patients randomized to placebo.
Of those with comorbid conditions, 14 (74%) of 19 in the sertraline group and 14 (82%) of 17 in the placebo group had 1 comorbid diagnosis. Three (16%) of 19 in the sertraline group and 2 (12%) of 17 in the placebo group had 2 comorbid diagnoses; the remainder had 3 or more disorders. As shown in Table 1 , the most common comorbidpsychiatricdiagnosiswasattention-deficit/hyperactivity disorder, followed by tic disorders, depression, anxiety disorders, and learning disorders.
Drug Dosing
Reflecting the protocol requirement of forced upward dosage titration to a targeted maximum dosage of 200 mg/d, the mean dosage of sertraline hydrochloride and placebo at end point were 167 mg/d and 180 mg/d, respectively. Among those treated with sertraline hydrochloride, 30 (57%) of 53 children and 32 (82%) of 39 adolescents were receiving a dosage of 200 mg/d at end point. Trough plasma levels of sertraline and its primary active metabolite, desmethylsertraline, normalized for body weight, were not significantly correlated with age or sex and did not predict clinical response in those treated with sertraline.
Efficacy
The effects of sertraline and placebo on the CY-BOCS and NIMH GOCS, CGI-S, and CGI-I ratings at end point are summarized in Table 2 . On the most conservative efficacy analyses, sertraline-treated patients exhibited significantly greater improvement than those taking placebo on the CY-BOCS (P = .005) and NIMH GOCS (P = .02) and CGI-I scale (P = .002). There was a trend favoring sertraline over placebo at end point on the NIMH CGI-S scale that failed to reach the threshold for statistical significance (P = .09). Similar but slightly more robust outcomes favoring sertraline were seen in patients who completed all 12 weeks of the study. Figure 2 , Figure 3 , and Figure 4 depict the week-by-week scores on the CY-BOCS, NIMH GOCS, and NIMH CGI-I scale for observed cases (available individuals at any point) and at end point (all patients using last observation carried forward). Group mean differences suggestive of greater improvement in the sertraline group than the placebo group are apparent at all study visits subsequent to the end of week 2. Table 3 presents responder analyses, defined on the CY-BOCS as a greater than 25% decrease in OCD symptoms and on the NIMH CGI scales as much or very much improved. Statistically significant differences favoring sertraline over placebo are apparent on both measures.
Age, race, sex, body weight, baseline OCD score, baseline depression score, comorbidity, socioeconomic status, and plasma sertraline and desmethylsertraline levels did not predict the outcome of treatment.
Safety
The average length of treatment for the sertraline group was 74.8 days and for the placebo group it was 75.9 days of 94 possible double-blind treatment days. Seventy-four (80%) of the 92 patients treated with sertraline and 82 (86%) of the 95 individuals treated with placebo completed the 12 weeks of double-blind treatment. Of the 31 patients (18 in the sertraline group and 13 in the placebo group) who discontinued treatment during the doubleblind treatment period, only 3 sertralinetreated and 2 placebo-treated individuals discontinued the study because of insufficient clinical response.
As shown in Figure 1 , 12 (13%) of 92 patients treated with sertraline and 3 (3.2%) of 95 placebo-treated patients discontinued treatment because of an adverse medical event (P = .02). Time to discontinuation did not differ between groups. Table 4 summarizes the incidence of adverse events that were statistically associated with sertraline in contrast with placebo treatment. A patient reporting more than 1 episode of the same complaint, even of differing severity, was counted once using the highest level of severity. Among all adverse experiences, there was a statistically significant difference (PϽ.05) in incidence between the sertraline and placebo treatment groups for insomnia, nausea, agitation, and tremor. The majority of adverse experiences fell in the mild-to-moderate range. Importantly, only 2 patients discontinued treatment because of adverse experiences while receiving a dosage of sertraline hydrochloride of less than 100 mg/d. There were no statistically significant differences in laboratory abnormalities between sertraline-treated patients and placebo-treated patients, and no patients taking sertraline discontinued the study because of laboratory abnormalities. There were no statistically significant differences between the sertraline and placebo groups in blood pressure or pulse, and no clinically significant electrocardiographic abnormalities emerged in either treatment group. A similar percentage of sertraline-treated patients and placebotreated patients developed electrocardiographic changes, none of which were clinically significant. The mean change in body weight from baseline to final visit of +0.31 kg among the sertraline-treated patients and +1.13 kg among the placebotreated patients was statistically significant (PϽ.05) but is of minimal clinical importance.
COMMENT
In what is, to our knowledge, the largest placebo-controlled trial of pharmacotherapy for pediatric OCD conducted to date, children and adolescents treated with sertraline fared better than those receiving placebo on 3 of the 4 main dependent measures. Statistically and clinically significant group mean differences emerged at week 3 and persisted for the duration of the study. Eighty percent of sertralinetreated patients and 86% of placebotreated patients completed treatment. Insomnia, nausea, agitation, and tremor were more common in those receiving sertraline, and more sertraline-treated patients than placebo-treated patients discontinued treatment prematurely because of adverse events. No adverse effects attributable to sertraline use were apparent on vital sign measurement or laboratory or electrocardiographic studies. Thus, we conclude that sertraline appears to be a safe and effective short-term treatment for pediatric OCD.
Because this study used a forced upward titration procedure, no firm statement regarding the relationship between dose and overall efficacy, speed of improvement, or adverse effects can be made. However, experts generally agree that the SSRIs as a group are better tolerated than the nonselective SRI clomipramine. 26 In a study of sertraline in adults with OCD, the most frequently occurring adverse events were nausea, insomnia, somnolence, diarrhea, and decreased libido. 9 A similar adverse effect profile was noted in this study, with the extent of adverse effects in the sertraline group at least in part a function of rapid upward titration to maximum dosages. Importantly, the present study failed to reveal significant differences in sertraline's adverse effect profile for children (aged 6-12 years) or adolescents (aged 13-17 years). Thus, the same dosage regimen used in adults appears appropriate for children and adolescents, with dosage tailored to the individual patient as a function of benefits and adverse effects. 10, 26 In this regard, a previous fixed-dose study of sertraline in adults with OCD demonstrated that 50-, 100-, and 200-mg dosage conditions were, on average, equal in efficacy. 9 Similar conclusions were seen in a fixed-dose study of fluoxetine, also in adults with OCD. 27 In both studies, adverse effects appeared to increase with higher doses. 9, 27 The magnitude of improvement seen in this study is comparable with that seen in other flexible-dose clinical trials of SRIs for OCD in adults 28 and youth. 13, 19, 29 Hence, to remain consistent with expert recommendations regarding SRI dosing in OCD, 10, 26 clinicians would be well advised to begin with 50 mg/d of sertraline hydrochloride, moving to maximum dosages by 6 to 8 weeks in nonresponders or partial responders for an adequate acute trial duration of 10 to 12 weeks.
In contrast with tricyclic antidepressants, including clomipramine, which have been reported to cause quinidinelike cardiotoxicity in children and adolescents, [30] [31] [32] the SSRIs show negligible cardiovascular effects. 15, 33 In this context, the absence in this study of significant electrocardiographic changes associated with sertraline is reassuring, and, absent specific indications for doing so, no generic requirement for monitoring cardiovascular or electrocardiographic parameters during sertraline treatment is apparent.
Consistent with findings from other pediatric OCD studies, age, sex, and other measured baseline parameters, including extent of comorbidity, did not predict response to treatment. However, 2 patients who discontinued the study prematurely despite receiving active drug previously were taking medication for attention-deficit/hyperactivity disorder. Although concomitant pharmacotherapy was an exclusion criterion in this study, expert clinical recommendations favor concomitant treatment with a psychostimulant and an SSRI for youth with both attention-deficit/hyperactivity disorder and OCD. 14, 26 Although treatment with sertraline provided clinically meaningful benefits, as in other studies of SRIs in OCD, the average sertraline-treated patient remained in the mildly ill range on the CY-BOCS at the end of treatment. Accordingly, most experts agree that the probability of clinical normalization is enhanced by combining pharmacotherapy with OCD-specific cognitive-behavioral psychotherapy. 26, 34 Although current treatments are not generally curative, given a correct diagnosis and skillful treatment most children and adolescents with OCD will improve considerably.
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